medigraphic.com

2019, Number 1

<< Back Next >>

Rev Med MD 2019; 10.11 (1)

Standard of care-impact in Diabetes Mellitus Type 2: DISCOVER Mexican cohort

González-Gálvez G, Aguilar-Salinas CA, Arechavaleta-Granell MR, Mehta R, Padilla-Padilla FG, Vázquez-Méndez E, Violante-Ortiz RM, Silva-Giordano AI

Language: Spanish
References: 33
Page: 2-9
PDF size: 593.27 Kb.


ABSTRACT

Introduction. Mexico occupies the sixth place of prevalence of diabetes mellitus type 2; between 2000 and 2012, the incidence of this entity increased by 59.6%. The aim of this study was to describe the therapeutic trends in Mexican T2DM (type 2 diabetes mellitus) patients whom initiated second-line therapy.
Material and Methods. DISCOVER T2DM study is a global, non-interventional, prospective and observational trial. We are reporting the baseline data of the Mexican cohort. Sites that would be as representative as possible of the management of patients with T2DM in Mexico were selected. Physicians recorded data regarding first and second-line therapy, time to initiation of second-line therapy and the antidiabetic drugs used. HbA1c and other metabolic parameters were also recorded.
Results. 455 Mexican patients with T2DM with a mean age of 56.8 ± 10.7 [median 57.8 (IQR 49.2, 63.6)] years with concomitant medical conditions were included. Mean HbA1c was 8.9 ± 1.6% [median of 8.6 (IQR 7.9, 9.8) (74 mmol/mol)]. The mean duration of first-line therapy was 7.2 ± 7.5 [median 5.0 (IQR 2.1, 10.4)] years and the most common drugs used were metformin (MET) (83.1%) and sulphonylureas (SU) (9.9%). The main reason for change of therapy was lack of efficacy (92.1%). The most common second-line therapy combination was MET+SU (47.3%).
Discussion. An earlier initiation of second-line therapies is needed, since the delay in intensification of therapy could be associated with reduced glycemic control and the development of complications.


REFERENCES

  1. IDF Diabetes Atlas 2016: www.diabetesatlas.org. ISBN: 978-2-930229-87-4.

  2. Encuesta Nacional de Salud y Nutricion 2012. Resultados Nacionales http://ensanut.insp.mx/doctos/ENSANUT2012_ PresentacionOficialCorta_09Nov2012.pdf

  3. Barquera S, Campos-Nonato I, Aguilar-Salinas C, Lopez-Ridaura R, Arredondo A, Rivera-Dommarco J. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Globalization and Health 2013, 9:3.

  4. International Diabetes Federation. IDF Atlas. Sixth edition, 2013.www.idf.org/diabetesatlas

  5. Villalpando S, Rojas R, Shamah-Levy T, Ávila MA, Gaona B, De la Cruz V, Rebollar R, Hernández L. Prevalence and distribution of type 2 Diabetes mellitus in Mexican adult population. A probabilistic survey. Salud Publica Mex 2010;52 suppl 1:S19-S26.

  6. International Diabetes Federation. Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes, 2012. https://www.idf.org/search.html?searchword=gui delines&searchphrase=all

  7. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Research and Clinical Practice. 2014;103: 150–160.

  8. E, Mallinger L, Abbott-Klafter J, Guerrero R, Villalpando S, Lopez Ridaura R, Aekplakorn W, Naghavi M, Lim S, Lozano R, JL Murraya C. Managemen tofdiabetesandas sociated cardiovascular risk factors in seven countries: a comparison of datafrom national health examination surveys. Bull World Health Organ 2011;89:172–183.

  9. Barcelo A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas. Rev Panam Salud Publica/Pan Am J Public Health 2001;10(5):300-308.

  10. Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia Edición 2013. Revista de la asociación Latinoamericana de diabetes.

  11. World Health Organization. Global Report on Diabetes. http://www.who.int

  12. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum?. Indian J Endocrinol Metab. 2016 Jul-Aug; 20(4): 546–551. doi: 10.4103/2230- 8210.183480

  13. 13 . International Diabetes Federation. Recommendations For Managing Type 2 Diabetes In Primary Care, 2017. www.idf.org/managingtype2- diabetes

  14. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018; 41(Supplement 1): S1-S2.

  15. 15.Introduction: Standards of Medical Care in Diabetes—2018 Diabetes Care Jan 2018, 41 (Supplement 1) S1-S2.

  16. International Diabetes Federation. Access to Medicines and Supplies for People with Diabetes. Br ussels, Belgium: Inter national Diabetes Federation, 2016. www.idf.org/accesstomedicine

  17. American Association of Clinical Endocrinologist and American College of Endocrinology – Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015 https://www.aace.com/files/dm-guidelinesccp. pdf.

  18. Khunti K, Gomes MB, Pocock S, Shestakova MV, Pintat S, Fenici P, Hammar N, Medina J. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. Published online 22 August 2017.

  19. Khunti K, Godec TR, Medina J, Garcia-Alvarez L, Hiller J, Gomes MB, Cid-Ruzafa J, Charbonnel B, Fenici P, Hammar N, Hashigami K, Kosiborod M, Nicolucci A, Shestakova MV, Ji L, Pocock S. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. Diabetes Obes Metab. Published online 17 August 2017.

  20. Gakidou E, Mallinger L, Abbott-Klafter J, Guerrero R, Villalpando S, Lopez Ridaura R, Aekplakorn W, Naghavi M, Lim S, Lozano R, JL Murraya C. Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of datafrom national health examination surveys. Bull World Health Organ 2011;89:172–183.

  21. Mateo JF, Gil-Guillen VF, Mateo E, Orozco D, Carbayo JA, Merino J. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006; 60:422–428.

  22. 22.Safford MM, Shewchuk R, Qu H, Williams JH, Estrada CA, Ovalle F, et al. Reasons for Not Intensifying Medications: Differentiating “Clinical Inertia” from Appropriate Care. J Gen Intern Med 22(12):1648–55.

  23. Barquera S, Tovar-Guzman V, Campos-Nonato I, Gonzalez-Villalpando C, Rivera-Dommarco J: Geography of diabetes mellitus mortality in Mexico: an epidemiologic transition analysis. Arch Med Res 2003, 34(5):407–414.

  24. 24.Ji L, Bonnet F, Charbonnel B, Gomes MB, Kosiborod M, Khunti K, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Fenici P, Hammar N, Hashigami K, Macaraeg G, Surmont F, Medina J. Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. J Diabetes Complications 2017;31(7):1188–96.

  25. 25.Escobedo J, Buitron LV, Velasco MF, Ramirez JC, Hernandez R, Macchia A, Pellegrini F, Schargrodsky H, Boissonnet C, Champagne BM. High prevalence of diabetes and impaired fasting glucose. Diabet. Med. 2009;26: 864–871.

  26. 26.Villalpando S, Rojas R, Shamah-Levy T, Ávila MA, Gaona B, De la Cruz V, Rebollar R, Hernández L. Prevalence and distribution of type 2 Diabetes mellitus in Mexican adult population. A probabilistic survey. Salud Publica Mex 2010;52 suppl 1:S19-S26.

  27. 27.Gómez-Dantés O, Sesma S, Becerril VM, Knaul FM, Arreola H, Frenk J. Sistema de salud de México. Salud pública Méx [online]. 2011, vol.53, suppl.2

  28. 28.Gakiduo E, Mallinger L, Abbott-Klafter J, Guerrero R, Villalpando S, Lopez Ridaura R, Aekplakorn W, Naghavi M, Lim S, Lozano R, JL Murraya C. Managemen tofdiabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys. Bull World Health Organ 2011;89:172–183.

  29. 29.Barquera S, Campos-Nonato I, Hernández-Barrera L, Flores M, Durazo-Arvizu R, Kanter R, Rivera JA. Obesity and central adiposity in Mexican adults: results from the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex 2009;51 suppl 4:S595-S603.

  30. Nusca A, Tuccinardi D, Albano M, Cavallaro C, Ricottini E, Manfrini S, et al. Glycemic Variability in the Development of Cardiovascular Complications in Diabetes. Diabetes Metab Res Rev. 2018 20:e3047.

  31. 31.The GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017;377:13-27.

  32. 32.Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S. Pharmacologic Differences of Sulfon y lureasand the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. 2017 Nov;40(11):1506-1513

  33. Peters AL. “Really Good” New Guidelines for T2 Diabetes. Medscape.2018.




2020     |     www.medigraphic.com